June 19, 2019
DURHAM, North Carolina and NESS ZIONA, Israel, June 18, 2019 /PRNewswire/ — Atox Bio, a late stage clinical company developing immunotherapies for critically ill patients, today announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).  Reltecimod is...
Scientific report indicates that more research is needed into how general practitioners examine for and treat throat infections. Both to help prevent life-threatening bacterial invasion and to keep track on use of antibiotics. General practitioners in Denmark conduct a total of 1.2 million examinations for throat infection every year, which means that one in five...


Open for applications for postdoc scholarships
11. July 2019
Shorter hospital stays after hip and knee surgery
8. July 2019
The Lundbeck Foundation is seeking new fellows
8. July 2019


Lundbeckfonden Ventures

Lundbeckfonden Emerge